ISSN: 0970-938X (Print) | 0976-1683 (Electronic)
An International Journal of Medical Sciences
Objective: To make a research on the prognosis factors of non-hodgkin lymphoma (NHL) cases, and discuss how to improve the prognosis as far as possible.
Methods: To collect 200 cases of NHL in The Second Affiliated Hospital of Dalian Medical University from January 1st 2008 to January 1st 2013, except for the withdraw and the untreated, 172 cases were in the study with the follow-up visit information. To analyse the data by SPSS17.0 and compare the survival rate by Kaplan-Meier. To analyse the effects of different factors on the patients’ prognosis. To use Cox model to analysis the single factor into multi-factor.
Results: Except for the withdraw and the patients untreated, there were 172 cases in our research. The survival rate of 1 year, 3 years, 5 years is 72.7%, 50.6% and 36.0%. Analysed by single factor, the factors had an influence on the prognosis were age, Ann Arbor-Cotswold’s, IPI, LDH, general symptom, pathological type and therapy scheme. There was no evidence confirming sex, first zone, bone marrow puncture, extracapsular extension were the prognosis factors. Results: (1) Age: Patients below 60 years obviously had a better prognosis than them at or after 60. (2) Ann Arbor-Cotswold’s: Patients at 1st or 2nd stage had a better prognosis than those at 3rd or 4th stage. (3) IPI: low risk (0-1 score), lowintermediate risk (2 scores), high high intermediate risk (3 scores) and high risk (4-5 scores). The higher IPI was the worse prognosis would be. (4) The level of serum LDH: patients with a higher level would have a worse prognosis than the ones with it normal. (5) General symptom: Patients without general symptoms had a better prognosis. (6) Pathological type: NHL from B lymphocyte had a better prognosis than those from NK/T. To make a further analysis on B cell subgroups, there was a statistic difference among them. On the contrary, there was no statistic difference among the NK/T’s. (7) Therapy scheme: In the 1st or 2nd stage group, the therapy scheme didn’t affect the prognosis much, but comprehensive therapy was much better than chemotherapy or radiotherapy alone in the 3rd of 4th stage.
Conclusion: